Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy
Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy
复制标题
DOI：
10.1016/j.canlet.2017.09.037
复制
发表时间：
2017-12-28
期刊：
影响因子：
9.7
通讯作者：
Eisenbrey, John R.
中科院分区：
文献类型：
--
作者：
Daecher, Annemarie;Stanczak, Maria;Eisenbrey, John R.
肝细胞癌（HCC）是全球第三大癌症死亡原因，也是美国增长最快的恶性肿瘤。由于5年生存率低于12%，因此需要对HCC进行有效的治疗。目前对HCC的治疗包括微波和射频消融、高强度聚焦超声、肝移植、手术切除和局部栓塞。然而，这些方法中的每一种都有一定的局限性，因此必须在治疗前开发用于致敏肿瘤的改进方法。我们假设使用超声触发微泡破坏（UTMD）通过诱导血管内皮细胞凋亡来使肿瘤对放疗敏感，将选择性地使恶性组织对放疗敏感并改善结果。为了测试这一点，在18只裸鼠的右肝叶中接种Hu7.5 HCC细胞，并在肿瘤形成后接受5戈伊放疗、UTMD或放疗前的UTMD。与单纯放疗相比，放疗联合UTMD治疗后7天肿瘤生长减少170%，中位生存时间延长3.2倍。这些结果表明，UTMD与放疗联合治疗HCC时是一种有效的辅助治疗（c）2017 Elsevier B.V.版权所有。
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide and the fastest growing malignancy in the United States. With a 5-year survival rate below 12%, effective therapies for HCC are needed. Current treatments for HCC include microwave and radiofrequency ablation, high intensity focused ultrasound, liver transplant, surgical resection, and localized embolizations. However, each of these approaches has some limitation, making it imperative to develop improved methods for sensitizing tumors prior to therapy. We hypothesized that the use of ultrasound-triggered microbubble destruction (UTMD), which sensitizes tumors to radiotherapy by inducing vascular endothelial cell apoptosis, will selectively sensitize malignant tissue to radiotherapy and improve outcomes. To test this, 18 nude rats were inoculated in the right liver lobe with Hu7.5 HCC cells and after tumor formation, received 5 Gy radiotherapy, UTMD, or UTMD prior to radiotherapy. Compared to radiotherapy alone, there was a 170% reduction in tumor growth 7 days post treatment and a 3.2X improvement in median survival time when radiotherapy was combined with UTMD. These results indicate that UTMD is an effective adjunct when combined with radiotherapy to treat HCC (c) 2017 Elsevier B.V. All rights reserved.